Please upgrade your browser.
In a stunning example of when treatment might be worse than the disease, a large review of Medicare records finds that older people with small kidney tumors were much less likely to die over the next five years if doctors monitored them instead of operating right away.
Final overall survival results from the phase III study of Aveo Pharmaceuticals' (AVEO_) kidney cancer drug tivozanib were released Tuesday night, and as expected, tivozanib-treated patients were at a greater risk of death than those treated with Onyx Pharmaceuticals' (ONXX_) Nexavar.
Join us March 14 for a day-long live web chat with our members in 102 nations. Celebrate World Kidney Day with your friends from the Kidney Cancer Association.
The University of North Carolina will be hosting its first conference for kidney cancer patients and their families on Saturday, February 23, 2013
The anticancer drug Sutent (sunitinib) does not cause tumors to grow faster after treatment ends, according to a new study.
A patient with pancreatic neuroendocrine tumor (PNET) treated at 1.0 mg/kg remained on study with stable disease (SD) for 18 months, and two patients with renal cell carcinoma (RCC) treated at 1.0 mg/kg remained on study with SD for approximately 8-12 months.
Consumers working with the Cancer Cooperative Trials Groups (CCTGs), and consumers more broadly, now have access to a suite of learning and support initiatives to enhance knowledge and skills in partnering with researchers to conduct quality patient-centred clinical trial research.
Acceleron Initiates Phase 2 Study of Dalantercept (ACE-041) to Treat Patients with Metastatic Renal Cell Carcinoma
Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.
The activity of systemic agents after progression when using vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibition (TKI) and mammalian target of rapamycin (mTOR) inhibition in patients with metastatic renal cell carcinoma (mRCC) is poorly characterized.
Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival
CUB domain-containing protein 1 (CDCP1) is a transmembrane protein that is highly expressed in stem cells and frequently overexpressed and tyrosine-phosphorylated in cancer. CDCP1 promotes cancer cell metastasis...
|Powered by NeonCRM|